trial · primary record
Canvuparatide
Hypoparathyroidism
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 160 |
| Primary completion | 2029-08 |
| Primary endpoint | To evaluate the effect of pooled weekly doses of canvuparatide on the proportion of responder patients at week 26. |
| Registry ID | NCT07699471 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:32:50.209Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07699471
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.